Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European randomized study of screening for prostate cancer

Journal of the National Cancer Institute

Volumn 95, Issue 12, 2003, Pages 868-878

  Draisma, Gerrit ^a   Boer, Rob ^a   Otto, Suzie J ^a   van der Cruijsen, Ingrid W ^a   Damhuis, Ronald A M ^b   Schröder, Fritz H ^a   de Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Rotterdam   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; HUMAN; LIFESPAN; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SIMULATION; TIME; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EUROPE; IMMUNOLOGY; MASS SCREENING; METHODOLOGY; MIDDLE AGED; NETHERLANDS; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

AGED; EUROPE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, BIOLOGICAL; NETHERLANDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0038275923     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.12.868     Document Type: Article

References (37)

1. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
2. Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Levesque J, et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 2000;45:19-35.
3. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24.
4. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schoenitzer D, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001;58:417-24.
5. Feuer EJ, Merrill RM, Hankey BJ. Cancer surveillance series: interpreting trends in prostate cancer-part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91:1025-32.
6. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BJ. Cancer surveillance series: interpreting trends in prostate cancer-part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91:1033-9.
7. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000;92:613-21.
8. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA". Int J Cancer 2001;92:893-8.
9. Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996;3:97-104.
10. de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002;97:237-44.
11. de Koning HJ, Liem M, Baan CA, Boer R, Schröder FH. Prostate cancer mortality reduction by screening; power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002;98:268-73.
12. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21:251S-72S.
13. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001;19:1619-28.
14. Hugosson J, Aus G, Carlsson S, Eriksson H, Lilja H, Lodding P, et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 2000;85:1078-84.
15. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994;152(5 Pt 2):1743-8.
16. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344:1594-8.
17. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
18. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954;68: 603-16.
19. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-6.
20. Watanabe M, Nakayame T, Shiraishi T, Stemmermann GN, Yatani R. Comparative study of prostate cancer in Japan versus the United States; a review. Urol Oncol 2000;5:274-83.
21. Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998;9:1297-300.
22. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
23. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998;159:1368-72.
24. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995;87:1217-23.
25. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed 1985;20:79-93.
26. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999;32:13-33.
27. Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schröder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 1999;84:437-41.
28. International Union against Cancer (UICC). TNM classification of malignant tumours. 4th ed. 2nd revision. Berlin (Germany): Springer Verlag; 1992. p. 141-4.
29. Visser O, Coebergh JW, Schouten LJ. Incidence of cancer in the Netherlands, 1991. Utrecht (The Netherlands): The Netherlands Cancer Registry; 1994. p. 13, 45.
30. Spapen SJ, Damhuis RA, Kirkels WJ. Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry. BJU Int 2000;85:474-80.
31. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schröder FH, et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003;105:394-9.
32. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001;166:1679-83.
33. Djavan B, Mazal P, Zlotta A, Wammack R, Ravery V, Remzi M, et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate 2001;47:111-7.
34. Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schroeder FH, van der Kwast TH. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 2000;56:617-21.
35. Pearson JD, Morrell CH, Landis PK, Carter HB, Brant LJ. Mixed-effects regression models for studying the natural history of prostate disease. Stat Med 1994;13:587-601.
36. Bazaraa MS, Sherali HD, Shetty CM. Nonlinear programming: theory and algorithms. New York (NY): John Wiley and Sons; 1993. p. 353.
37. Barton RR, Ivey JS. Nelder-Mead simplex modifications for simulation optimization. Manage Sci 1996;42:954-73.